AIMS: To provide new insights into characterising solid cell nests and gain information that might help distinguish between solid cell nests and C cells. METHODS: Thyroid tissue specimens from patients who had undergone prophylactic thyroidectomy for familial medullary thyroid cancer were immunostained for calcitonin, carcinoembryonic antigen, and galectin 3. RESULTS: Solid cell nests displayed a strong and diffuse staining for carcinoembryonic antigen and galectin 3, but not for calcitonin. C cells located at the periphery of solid cell nests and in neighbouring follicles expressed both calcitonin and carcinoembryonic antigen but not galectin 3. These three markers were positive in medullary thyroid carcinoma. CONCLUSION: Galectin 3 immunoreactivity permits a better characterisation and differentiation between solid cell nests and C cells, avoiding the misidentification of two biologically and clinically different thyroid structures.
AIMS: To provide new insights into characterising solid cell nests and gain information that might help distinguish between solid cell nests and C cells. METHODS: Thyroid tissue specimens from patients who had undergone prophylactic thyroidectomy for familial medullary thyroid cancer were immunostained for calcitonin, carcinoembryonic antigen, and galectin 3. RESULTS: Solid cell nests displayed a strong and diffuse staining for carcinoembryonic antigen and galectin 3, but not for calcitonin. C cells located at the periphery of solid cell nests and in neighbouring follicles expressed both calcitonin and carcinoembryonic antigen but not galectin 3. These three markers were positive in medullary thyroid carcinoma. CONCLUSION:Galectin 3 immunoreactivity permits a better characterisation and differentiation between solid cell nests and C cells, avoiding the misidentification of two biologically and clinically different thyroid structures.
Authors: Antongiulio Faggiano; Monique Talbot; Ludovic Lacroix; Jean Michel Bidart; Eric Baudin; Martin Schlumberger; Bernard Caillou Journal: Clin Endocrinol (Oxf) Date: 2002-12 Impact factor: 3.478
Authors: A Bartolazzi; A Gasbarri; M Papotti; G Bussolati; T Lucante; A Khan; H Inohara; F Marandino; F Orlandi; F Nardi; A Vecchione; R Tecce; O Larsson Journal: Lancet Date: 2001-05-26 Impact factor: 79.321
Authors: María José Ríos Moreno; Hugo Galera-Ruiz; Manuel De Miguel; María Inés Carmona López; Matilde Illanes; Hugo Galera-Davidson Journal: Endocr Pathol Date: 2011-03 Impact factor: 3.943